Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers
The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Jesse Karmazin
CEO of the blood transfusion company Ambrosia.
Jesse Karmazian is the CEO of the blood transfusion company Ambrosia which he founded in 2014. He is based in the United States.
Karmazin graduated from Princeton University in 2007. He would earn his MD in 2014 from Stanford University.
Visit website: https://everipedia.org/wiki/lang_en/jesse-karmazin
See also: 
Ambrosia
- Offers young blood plasma transfers after running a trial in 2016-18
Details last updated 12-Nov-2019
Jesse Karmazin Blog Posts
03-Feb-2020
Jesse Karmazin News
Ambrosia young blood plasma treatments relaunched
OneZero - 08-Nov-2019
No further clinical trials planned, but some interesting results from initial trial
Read more...Young blood as a key to living longer
Wired - 09-May-2018
GDF11 is a protein in the blood, which can stimulate cell growth and repair
Read more...Young blood reduces ageing biomarkers in humans
New Scientist - 31-May-2017
Update on Ambrosia trial that gives blood plasma from under 25s to older people. Recipients have...
Read more...Young blood antiaging trial raises questions
Science - 01-Aug-2016
Ambrosia (https://www.ambrosiaplasma.com/) young plasma trial is open to anyone 35 and older. Pa...
Read more...
